Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 655

Sort by

Sort Order Select

Journal Articles

MCL-1 and BCL-XL: blood brothers

Miriam Erlacher, Verena Labi

Blood (2021) 137 (14): 1850–1851.

https://doi.org/10.1182/blood.2020010569

Published: 2021

Journal Articles

Requirement for antiapoptotic MCL-1 during early erythropoiesis

Meghan E. Turnis, Ewa Kaminska, Kaitlyn H. Smith, Brittany J. Kartchner, Peter Vogel, Jonathan D. Laxton, Richard A. Ashmun, Paul A. Ney, Joseph T. Opferman

Blood (2021) 137 (14): 1945–1958.

https://doi.org/10.1182/blood.2020006916

Published: 2021

Includes: Supplemental data

Journal Articles

IKAROS and CK2 regulate expression of BCL-XL and chemosensitivity in high-risk B-cell acute lymphoblastic leukemia

Blood (2020) 136 (13): 1520–1534.

https://doi.org/10.1182/blood.2019002655

Published: 2020

Includes: Supplemental data

Journal Articles

Pre-Clinical Efficacy of Co-Treatment with KDM1A (LSD1) Inhibitor and Ruxolitinib or BET Inhibitor Against Post-MPN-sAML Blast Progenitor Cells

Warren Fiskus, BSc,PhD, Christopher Peter Mill, PhD BA, Vrajesh Karkhanis, PhD, Bernardo H Lara, Prithviraj Bose, MD, Lucia Masarova, Tapan M. Kadia, MD, Nancy Shao, Isean Bhalla, James V Maher, Joseph D. Khoury, MD, Sunil Sharma, MD, Taghi Manshouri, PhD, Srdan Verstovsek, MD PhD, Kapil N. Bhalla, MD

Blood (2019) 134 (Supplement_1): 1274.

https://doi.org/10.1182/blood-2019-130783

Published: 2019

Journal Articles

BCL-Xl Expression Is Druggable Biomarker Associated with a Poor Clinical Outcome in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Juan J. Gu, MD PhD, Michael Vacaro, Kris Attwood, PhD MS, Cory Mavis, MSc, Pallawi Torka, MD, Matthew J. Barth, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2019) 134 (Supplement_1): 1629.

https://doi.org/10.1182/blood-2019-128512

Published: 2019

Journal Articles

BCL-2 Is Expressed in Advanced Mastocytosis and Midaustorin Induces Venetoclax Sensitivity of Mast Leukemia Cell Lines

Danielle Canioni, MD, Josquin Moraly, MD, Ludovic Lhermitte, MD PhD, Laura Polivka, MD, Mélanie Féroul, Julien Rossignol, MD PhD, Laurent Frenzel, MD PhD, Michel Arock, pharmD, PhD, Patrice Dubreuil, PhD, Leila maouche-Chretien, PhD, Olivier Hermine, MD PhD

Blood (2019) 134 (Supplement_1): 1683.

https://doi.org/10.1182/blood-2019-131256

Published: 2019

Journal Articles

Identification of a New Targeted Therapy for T-Cell Acute Lymphoblastic Leukemia and Studies on Its Mechanism of Action

Kinjal Shah, MS, Julhash U. Kazi, PhD

Blood (2019) 134 (Supplement_1): 2752.

https://doi.org/10.1182/blood-2019-129823

Published: 2019

Journal Articles

A Novel BCL-2/BCL-Xl Dual Inhibitor Overcomes Ibrutinib-Resistance Conferred By the Upregulation of Integrin Pathway and BCL-Xl

Jing Deng, PhD, Tingting Mao, MS, Xiaojing Huang, PhD, Li Rui, Guangfeng Wang, PhD, Douglas D. Fang, MD PhD, Dajun Yang, MD PhD, Yifan Zhai, MD PhD

Blood (2019) 134 (Supplement_1): 2573.

https://doi.org/10.1182/blood-2019-128708

Published: 2019

Journal Articles

The Splicing Modulator GEX1A Exhibits Potent Anti-Leukemic Activity Both in Vitro and In Vivo through Inducing an MCL1 Splice-Switch in Pre-Clinical Models of Acute Myeloid Leukemia

Mark Sellin, Ryan Mack, Matthew C. Rhodes, Lei Zhang, PhD, Wei Wei, Peter Breslin, PhD, Stephanie Berg, DO, Suming Huang, PhD, Richard Taylor, PhD, Jiwang Zhang, MD

Blood (2019) 134 (Supplement_1): 2666.

https://doi.org/10.1182/blood-2019-132030

Published: 2019

Journal Articles

Individualized Mitochondrial Functional Approach to Combination of BCL-2 and MCL-1 Antagonism in Acute Myeloid Leukemia

Shruti Bhatt, PhD, Marissa Pioso, Elyse Ann Olesinski, Binyam Yilma, Leutz Buon, Sophia Adamia, PhD, Holly Zhu, Jeremy Ryan, Youzhen Wang, Morris Erick, Ensar Halilovic, David M. Weinstock, MD, Jacqueline S Garcia, MD, Anthony Letai

Blood (2019) 134 (Supplement_1): 2551.

https://doi.org/10.1182/blood-2019-131101

Published: 2019

Journal Articles

IGLL5-BCL2L1 Rearrangement with Loss of BCL2 Dependency As Mechanism of Venetoclax Resistance in Multiple Myeloma (MM)

Jean-Baptiste Alberge, Sarthak Sinha, BSc, Ranjan Maity, PhD, Arzina Jaffer, Justin Donovan, Madison Kong, Stephane Minvielle, PhD, Paola Neri, MD PhD, Nizar Bahlis, MD

Blood (2019) 134 (Supplement_1): 686.

https://doi.org/10.1182/blood-2019-131981

Published: 2019

Journal Articles

IRF4 Is Reciprocally Dysregulated Via NF-Κb-Dependent Expression and Loss-of-Function Mutations in Multiple Myeloma

Yun Dai, MD, Yue Sun, MS, Shaji K. Kumar, MD, Wei Wu, MD, Fengyan Jin, MD PhD

Blood (2019) 134 (Supplement_1): 687.

https://doi.org/10.1182/blood-2019-132051

Published: 2019

Journal Articles

Chidamide Combined with Decitabine Synergistically Induce Apoptosis of Acute Myeloid Leukemia By up-Regulating Perp gene In Vivo and in Vitro

Qing Li, MD, Yunfan Yang, MD, Yu Wu, MD

Blood (2019) 134 (Supplement_1): 536.

https://doi.org/10.1182/blood-2019-123876

Published: 2019

Journal Articles

Mechanistic Basis and Efficacy of Targeting β-Catenin-TCF7L2-JMJD6-MYC Axis to Overcome Resistance to BET Inhibitors

Christopher Peter Mill, PhD BA, Warren Fiskus, BSc,PhD, Dyana T. Saenz, PhD, Bernardo H Lara, Vrajesh Karkhanis, PhD, Taghi Manshouri, PhD, Isean Bhalla, Nancy Shao, James V Maher, Srdan Verstovsek, MD PhD, Kapil N. Bhalla, MD

Blood (2019) 134 (Supplement_1): 538.

https://doi.org/10.1182/blood-2019-125142

Published: 2019

Journal Articles

Linking Microenvironmental Signals to Metabolic Switches and Drug Responses in Chronic Lymphocytic Leukemia

Zhenghao Chen, Gaspard Cretenet, Hanneke ter Burg, Gabriela Andrejeva, Jeffrey C Rathmell, Francesco Forconi, MD DM, PhD FRCPath, Gerritje J. W. van der Windt, Arnon P. Kater, Eric Eldering

Blood (2019) 134 (Supplement_1): 479.

https://doi.org/10.1182/blood-2019-123005

Published: 2019

Journal Articles

Detection of Multiple Recurrent Novel BCL2 Mutations Co-Occurring with BCL2 Gly101Val in Patients with Chronic Lymphocytic Leukemia on Long Term Venetoclax

Piers Blombery, MBBS, Ella Thompson, PhD BSc, Tamia Nguyen, Xiangting Chen, PhD, Michelle McBean, Richard W Birkinshaw, PhD, Peter E Czabotar, PhD, Rachel Thijssen, Mary Ann Anderson, MBBS, PhD FRACP, FRCPA, John F. Seymour, MBBS, PhD FRACP, David Alan Westerman, MBBS, FRCPA, FRACP, David C.S. Huang, MBBS MRCP PhD, Andrew W. Roberts, MBBS, PhD

Blood (2019) 134 (Supplement_1): 171.

https://doi.org/10.1182/blood-2019-125457

Published: 2019

Journal Articles

Venetoclax in Combination with High-Dose Chemotherapy Is Active and Well-Tolerated in Children with Relapsed or Refractory Acute Myeloid Leukemia

Seth E Karol, MD, Thomas Alexander, MDMPH, Amit Budraja, PhD, Stanley Pounds, PhD, Kristin E Canavera, PhD, Lei Wang, MS, Joshua Wolf, MBBS, PhD, Jeffery M. Klco, MD PhD, Ahmed Hamed Salem, PhD FCP, Tammy Palenski, PhD, Norman J. Lacayo, MD, Ching-Hon Pui, MD, Joseph T. Opferman, PhD, Jeffrey Rubnitz, MD PhD

Blood (2019) 134 (Supplement_1): 178.

https://doi.org/10.1182/blood-2019-127716

Published: 2019

Journal Articles

DT2216, a BCL-XL Proteolysis Targeting Chimera (PROTAC), Is a Potent Anti T-Cell Lymphoma Agent That Does Not Induce Significant Thrombocytopenia

Yonghan He, MD, Raphael Koch, Vivekananda Budamagunta, Dongwen Lv, Sajid Khan, Xuan Zhang, Janet S Wiegand, Guangrong Zheng, David M. Weinstock, MD, Daohong Zhou

Blood (2019) 134 (Supplement_1): 303.

https://doi.org/10.1182/blood-2019-125820

Published: 2019

Journal Articles

The Combination of Dexamethasone and Ruxolitinib Synergistically Attenuates Disease Manifestations in a Preclinical Model of Hemophagocytic Lymphohistiocytosis

Lauren K. Meyer, Katherine Verbist, PhD, Sabrin Albeituni, PhD, Rachel Bassett, Michelle L. Hermiston, MD PhD, Kim E. Nichols, MD

Blood (2019) 134 (Supplement_1): 81.

https://doi.org/10.1182/blood-2019-129112

Published: 2019

Journal Articles

AT1412, a Patient-Derived Antibody in Development for the Treatment of CD9 Positive Precursor B-Acute Lymphoblastic Leukemia

Greta De Jong, Sophie E Levie, Remko Schotte, PhD, Wouter Pos, PhD, Daniel Go, Etsuko Yasuda, Madalina Cercel, Susan E van Hal-van Veen, Esmay Frankin, Anikó Szabó, MD, Julien Villaudy, PhD, Pauline M van Helden, PhD, Hans van Eenennaam, PhD, Hergen Spits, PhD, Anita W Rijneveld, MD PhD, Mette D Hazenberg, MD PhD

Blood (2019) 134 (Supplement_1): 4461.

https://doi.org/10.1182/blood-2019-127894

Published: 2019

NARROW

MCL-1 and BCL-XL: blood brothers

Requirement for antiapoptotic MCL-1 during early erythropoiesis

IKAROS and CK2 regulate expression of BCL-XL and chemosensitivity in high-risk B-cell acute lymphoblastic leukemia

Pre-Clinical Efficacy of Co-Treatment with KDM1A (LSD1) Inhibitor and Ruxolitinib or BET Inhibitor Against Post-MPN-sAML Blast Progenitor Cells

BCL-Xl Expression Is Druggable Biomarker Associated with a Poor Clinical Outcome in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

BCL-2 Is Expressed in Advanced Mastocytosis and Midaustorin Induces Venetoclax Sensitivity of Mast Leukemia Cell Lines

Identification of a New Targeted Therapy for T-Cell Acute Lymphoblastic Leukemia and Studies on Its Mechanism of Action

A Novel BCL-2/BCL-Xl Dual Inhibitor Overcomes Ibrutinib-Resistance Conferred By the Upregulation of Integrin Pathway and BCL-Xl

The Splicing Modulator GEX1A Exhibits Potent Anti-Leukemic Activity Both in Vitro and In Vivo through Inducing an MCL1 Splice-Switch in Pre-Clinical Models of Acute Myeloid Leukemia

Individualized Mitochondrial Functional Approach to Combination of BCL-2 and MCL-1 Antagonism in Acute Myeloid Leukemia

IGLL5-BCL2L1 Rearrangement with Loss of BCL2 Dependency As Mechanism of Venetoclax Resistance in Multiple Myeloma (MM)

IRF4 Is Reciprocally Dysregulated Via NF-Κb-Dependent Expression and Loss-of-Function Mutations in Multiple Myeloma

Chidamide Combined with Decitabine Synergistically Induce Apoptosis of Acute Myeloid Leukemia By up-Regulating Perp gene In Vivo and in Vitro

Mechanistic Basis and Efficacy of Targeting β-Catenin-TCF7L2-JMJD6-MYC Axis to Overcome Resistance to BET Inhibitors

Linking Microenvironmental Signals to Metabolic Switches and Drug Responses in Chronic Lymphocytic Leukemia

Detection of Multiple Recurrent Novel BCL2 Mutations Co-Occurring with BCL2 Gly101Val in Patients with Chronic Lymphocytic Leukemia on Long Term Venetoclax

Venetoclax in Combination with High-Dose Chemotherapy Is Active and Well-Tolerated in Children with Relapsed or Refractory Acute Myeloid Leukemia

DT2216, a BCL-XL Proteolysis Targeting Chimera (PROTAC), Is a Potent Anti T-Cell Lymphoma Agent That Does Not Induce Significant Thrombocytopenia

The Combination of Dexamethasone and Ruxolitinib Synergistically Attenuates Disease Manifestations in a Preclinical Model of Hemophagocytic Lymphohistiocytosis

AT1412, a Patient-Derived Antibody in Development for the Treatment of CD9 Positive Precursor B-Acute Lymphoblastic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only